CAR T-cell therapy: Reprogramming the immune system to treat cancer | Dr. Rob Weinkove

Dr. Robert Weinkove is Clinical Director of the Malaghan Institute, a biomedical research institute in Wellington, NZ. Rob is a blood specialist researching a cutting edge, personalised, cancer treatment known as Chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a treatment, which involves taking a patient’s own immune cells, reprogramming them and returning them back to the patient to fight the cancer. Rob and his team are developing a clinical trial to evaluate a “third generation” CAR T-cell therapy. He hopes that this will present a paradigm shift for treatment of lymphoma, and possibly for other cancers, in the future.